Close
FINDING CURES TOGETHER<sup>SM</sup>

Addressing Critical Questions in Ovarian Cancer Research and Treatment

View Program PDF (as of 9/28/17)

Sunday, October 1 

Monday, October 2

Tuesday, October 3

Wednesday, October 4


Sunday, October 1

Educational Session
Session Chairs: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts
4:00 p.m.-6:00 p.m.

Ovarian cancer: From prevention and early detection to biology, biomarkers, heterogeneity, and immunology
Anil K. Sood
Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, New York

Treatment of ovarian cancer: Present and future
Ursula A. Matulonis
Robert P. Edwards, University of Pittsburgh, Pittsburgh, Pennsylvania


Welcome Remarks / Opening Keynote Lecture
6:15 p.m.-7:30 p.m.

Welcome Remarks
Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas

Meeting the challenges in ovarian cancer
Joan S. Brugge, Harvard Medical School, Boston, Massachusetts


Opening Reception
7:30 p.m.-9:30 p.m.


Monday, October 2

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.


Plenary Session 1: DNA Damage and Repair
Session Chairs: Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts, and Roger A. Greenberg, University of Pennsylvania, Philadelphia, Pennsylvania
8:00 a.m.-10:00 a.m.

PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead?
Ursula A. Matulonis

Inhibition of ATR overcomes the PARP inhibitor resistance of BRCA-deficient cancer cell
Lee Zou, Massachusetts General Hospital Cancer Center / Harvard Medical School, Boston, Massachusetts

Mitotic progression connects DNA damage to activation of anti-tumor immune responses
Roger A. Greenberg

Cyclin E: Targeting cell cycle dependencies in CCNE1 amplified tumors*
Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania

Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition*
Monicka Wielgos-Bonvallet, NYU Langone Medical Center, New York, New York


Break
10:00 a.m.-10:30 a.m.


Plenary Session 2: Metabolic Changes in Ovarian Cancer
Session Chairs: Ernst R. Lengyel, University of Chicago, Chicago, Illinois, and Ahmed A. Ahmed, University of Oxford, Oxford, England
10:30 a.m.-12:30 p.m.

Discovery of IACS-10759, a novel oxidative phosphorylation inhibitor targeting critical cancer vulnerabilities
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, Texas

Stromal regulation of metastasis
Ernst R. Lengyel

Targeting micrometastasis for the treatment of ovarian cancer
Ahmed A. Ahmed

Kinase-mediated modulation of paclitaxel sensitivity in ovarian cancer
Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma*
Jennifer Xiao Ye Ji, University of British Columbia, Vancouver, BC, Canada


Free Time / Lunch on Own
12:30 p.m.-3:00 p.m.


Plenary Session 3: Tumor Microenvironment
Session Chairs: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Frances R. Balkwill, Barts Cancer Institute, London, England
3:00 p.m.-5:00 p.m.

New directions in tumor microenvironment
Anil K. Sood

Deconstructing and reconstructing the ovarian cancer microenvironment
Frances R. Balkwill

Translating preclinical observations into trials addressing changes in the tumor microenvironment
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas

Tumor-derived indoleamine 2,3- dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid derived suppressor cells in a murine model of ovarian cancer*
Adaobi E. Amobi, Roswell Park Cancer Institute, Buffalo, New York

Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis*
Mark A. Eckert, University of Chicago, Chicago, Illinois


Panel Discussion: Innovative Trial Design
Session Chair: Elise C. Kohn, CIB/CTEP/DCTD/NCI, Rockville, Maryland
5:00 p.m.-6:00 p.m.

Panelists:
Elise C. Kohn
Michael J. Birrer, UAB Comprehensive Cancer Center, Birmingham, Alabama

ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs. placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)*
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas


Poster Session A / Reception
6:00 p.m.-8:30 p.m.


Top of page


Tuesday, October 3

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.


Plenary Session 4: Drug Response and Resistance to Therapy
Session Chair: David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia, and Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas
8:00 a.m.-10:00 a.m.

Acquired chemotherapy resistance in high-grade serous ovarian cancer patients
David D. L. Bowtell

Systems approach to drug development
Gordon B. Mills

Exploiting synthetic lethality in the treatment of gynecological cancers
Christopher Lord, Cancer Research UK London Research Institute, London, England

Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer*
Claudia Iavarone, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts

Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer*
Anniina Färkkilä, University of Helsinki, Helsinki, Finland


Break
10:00 a.m.-10:30 a.m.


Plenary Session 5: Prevention and Early Detection
Session Chairs: Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas, and Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, Maryland
10:30 a.m.-12:30 p.m.

Early detection of ovarian cancer: An update
Robert C. Bast, Jr.

PapGene, PapSEEK, and PapDREAming for early detection of ovarian cancer
Ie-Ming Shih

Physical and in silico methods for improving sensitivity of detection of ctDNA for personalized medicine in high grade serous ovarian cancer
James D. Brenton, University of Cambridge, Cambridge, England

Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq*
Kevin M. Elias, Brigham and Women's Hospital, Boston, Massachusetts   

Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study*
Francesmary Modugno, University of Pittsburgh, Pittsburgh, Pennsylvania


Poster Session B / Lunch
12:30 p.m.-3:00 p.m.


Plenary Session 6: Exploiting Vulnerabilities in Rare Tumors
Session Chairs: David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, Texas, and David G. Huntsman, University of British Columbia, Vancouver, British Columbia, Canada
3:00 p.m.-5:00 p.m.

Progress and future directions in the management of low-grade serous cancer of the ovary
David M. Gershenson

Granulosa cell and other rare ovarian cancers: Genomic-derived diagnostics and emergent management strategies
David G. Huntsman

Therapeutic targeting ARID1A mutation in ovarian cancer
Rugang Zhang, The Wistar Institute, Philadelphia, Pennsylvania

Small cell carcinomas of the ovary: Strengths and weaknesses
Douglas A. Levine, New York University, New York, New York

The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma*
Darren Ennis, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom


Panel Discussion: Funding Opportunities and Advocacy Groups
5:00 p.m.-6:00 p.m.

Kiran Dhillon, Director of Scientific Programs, Rivkin Center for Ovarian Cancer Research, Seattle, Washington
Kathleen Gavin, Executive Director, Minnesota Ovarian Cancer Alliance, Minneapolis, Minnesota
Kristin Parello-Plesner, Strategic Director, OvaCure, Copenhagen, Denmark
Runsi Sen, Founder, President & CEO, Ovarcome, Houston, Texas
Katherine Taylor, Chief Executive, Ovarian Cancer Action, London, England
Annie E. Ellis, Patient Advocate, Ovarian Cancer Research Fund Alliance, White Plains, New York
Susan N. Perkins, Center for Cancer Training, National Cancer Institute, National Institutes of Health, Rockville, Maryland
Karen Wylie, Science Officer, Ripple Effect, in support of The Congressionally Directed Medical Research Programs (CDMRP), Frederick, Maryland


Top of page


Wednesday, October 4

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.


Plenary Session 7: Immunotherapy
Session Chairs: Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, New York, and David R. Spriggs, Memorial Sloan Kettering Cancer Center, New York, New York
8:00 a.m.-10:00 a.m.

Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy
Kunle Odunsi

How does the immune system contend with intratumoral heterogeneity in ovarian cancer?
Brad Nelson, BC Cancer Agency, Vancouver Island, British Columbia, Canada

Translating fundamental immunobiology into adoptive T cell therapy for ovarian cancer    
Daniel J. Powell, University of Pennsylvania, Philadelphia, Pennsylvania

Strategies for glycosylation-based immunotargeting of MUC16
David R. Spriggs

Epigenetic reprograming promotes an immunogenic ovarian tumor microenvironment and synergizes with adoptive transfer of engineered T cells expressing NY-ESO-1 specific T cell receptors*
Li Shen, Roswell Park Cancer Institute, Buffalo, New York


Break
10:00 a.m.-10:15 a.m.


Plenary Session 8: Genetics and Molecular Drivers
Session Chairs: Ronny I. Drapkin, University of Pennsylvania, Philadelphia, Pennsylvania, and Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada
10:15 a.m.-12:15 p.m.

Replication road blocks in Cyclin E-amplified ovarian cancers
Ronny I. Drapkin

Functional genetic architecture of serous ovarian cancer
Robert K. Rottapel

Genomic rearrangement signatures in high grade serous ovarian cancers
Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, Texas

TERT is frequently mutated in adult-type granulosa cell tumors of the ovary compared to other malignant sex cord-stromal tumors*
Jessica A. Pilsworth, University of British Columbia, Vancouver, BC, Canada

CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high grade serous carcinoma*
Josephine Walton, The University of Glasgow, Glasgow, United Kingdom


Closing Remarks / Departure
12:15 p.m.


*Short talk from proffered abstract


Top of page


#AACROvCa17